“…A total of 5616 publications for not meeting the selection criteria and 146 duplicated guidances were removed. Finally, 35 CPGs ((ABS) AoBS, 2018; (AGO) AGO, 2019a; (AGO) AGO, 2019b; (HIS) HiS, 2018; (RCR) RCoR, 2019; American Cancer Society, 2019; Asociación Española de Cirugía (AEC), 2017; Breast Expert Advisory Group/Northern Cancer Alliance, 2019; Canadian Agency for Drugs and Technologies in Health, 2019; China Anti‐Cancer Association, 2019; Ditsch et al, 2020; ESMO, 2019; Fisterra, 2019; Huang et al, 2019; Instituto Nacional de Colombia, 2017; Klarenbach et al, 2018; Mainiero et al, 2017; Migowski, Dias, et al, 2018; Migowski, Silva, et al, 2018; Migowski, Stein, et al, 2018; Ministry of Health Malaysia, 2019; Monticciolo et al, 2018; National Health Commission of the People's Republic of China, 2019; NCCN, 2019; Ontario, 2017; Pinder et al, 2018; Public Health England, 2017, 2019; Practice Bulletin Number 179, 2017; Qaseem et al, 2019; SEGO, SEOR, SEAP, SESPM, SEDIM, SEMNIM, 2017; Sociedad Española de Senología y Patología Mamaria, 2019; Uematsu et al, 2018; UHo, 2018; Urban et al, 2017) and 5 CSs ((ABSI) AoBSoI, 2017; (ASBS) ASoBS, 2017; Cardoso et al, 2018; The American Society of Breast Surgeons, 2019; Secretaría de Salud de México, 2019; 40 documents) were included for the final review (Table 1). Four CPGs and two CSs were in Spanish and the rest in English.…”